MedTrace Logo

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2026-04-23

No results posted yet for this study

Summary

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pancreatic Adenocarcinoma
  • Non-small Cell Lung Cancer (NSCLC)
  • Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
  • Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
  • Triple Negative Breast Cancer (TNBC)

Interventions

DRUG

GTAEXS617

Administered as specified in the treatment arm.

DRUG

SoC

Participants will receive selected SoC regimen (fulvestrant, paclitaxel + bevacizumab, pegylated liposomal doxorubicin, or capecitabine) administered as specified in the treatment arm.

Sponsors & Collaborators

  • Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Exscientia AI Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2028-01-31
Completion
2028-05-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05985655 on ClinicalTrials.gov